ZenNews› Health› Type 1 Diabetes Drug Delay Puts U.S. Insurers on … Health Type 1 Diabetes Drug Delay Puts U.S. Insurers on Defense Immunotherapy approval abroad pressures American payers to expand coverage By Oliver Walsh Jun 24, 2026 1 min read Share Share X Facebook WhatsApp Copy link How do you feel about this? 🔥 0 😲 0 🤔 0 👍 0 😢 0 Health Type Diabetes Drug Delay O Oliver Walsh Health & Climate Oliver Walsh analyses medical research, US health policy and climate science. You might also like › Health Pancreatic Cancer Pill Reshapes U.S. Oncology Spending Debate 08 Jun 2026 Health AI-Designed Vaccine Reaches U.S. Clinical Pipeline 07 Jun 2026 Health Ozempic Muscle Loss Fuels U.S. Drug Pipeline Race 09 Jun 2026 Health Wegovy Pill Form Puts U.S. Oral GLP-1 Market on Notice 12 Jun 2026 Health CAR-T Immune Reset Trial Puts Lupus Remission Within U.S. Reach 19 Jun 2026 Health Wegovy Pill Form Puts Pressure on U.S. Oral Drug Pipeline 21 Jun 2026 Also interesting › US Politics War Powers Rebuke Forces Trump Into Constitutional Corner 9 hrs ago Tech WhatsApp Power Shift Tests Meta's U.S. Regulatory Standing 13 hrs ago Tech AI Firms Use Free Home Services to Build Robot Labor Data 17 hrs ago Society Hidden Fee Crackdown Puts U.S. Ticket Platforms on Notice 21 hrs ago More in Health › Health HPV Vaccine Success Pressures U.S. to Close Coverage Gaps 21 Jun 2026 Health Wegovy Pill Form Puts Pressure on U.S. Oral Drug Pipeline 21 Jun 2026 Health CAR-T Immune Reset Trial Puts Lupus Remission Within U.S. Reach 19 Jun 2026 Health Wegovy Pill Form Puts U.S. Oral GLP-1 Market on Notice 12 Jun 2026 ← Health HPV Vaccine Success Pressures U.S. to Close Coverage Gaps
